Kiora Pharmaceuticals (NASDAQ: KPRX) is a clinical-stage ophthalmic biopharmaceutical company developing small molecule therapies for degenerative retinal diseases. Revenue, to the extent it exists, comes from government grants and milestone payments under collaboration and licensing agreements, not product sales. The company does not expect to generate product revenue until and unless its candidates complete clinical development and receive regulatory approval. As of December 31, 2025, Kiora held $8.7 million in cash and cash equivalents and $8.4 million in short-term investments, totaling $17.1 million, which management believes is sufficient to fund planned operations into late 2027. The lead candidate, KIO-301, is a photoswitch small molecule targeting vision restoration in retinitis pigmentosa patients; it received FDA orphan drug designation in March 2022 and completed Phase 1b dosing in September 2023. A Phase 2 trial was cleared to initiate in October 2024 in collaboration with partner TOI. The second pipeline asset is KIO-104. Kiora carries in-process research and development assets of approximately $2.1 million as of December 31, 2025, down from $6.7 million at December 31, 2024.

Revenue model

Milestone payments and collaboration revenue under licensing and research collaboration agreements, plus U.S. and foreign government grants recognized through subsidiaries Jade and Panoptes. No product revenue as of the filing date. Revenue fluctuates with timing of milestones met.

Products and services

KIO-301: a photoswitch small molecule designed to restore vision in patients with retinitis pigmentosa and other inherited or age-related degenerative retinal diseases by converting retinal ganglion cells into light-sensing cells. FDA orphan drug designation granted March 17, 2022. Phase 1b (ABACUS study) completed September 2023; Phase 2 cleared October 2024. KIO-104: second therapeutic asset in development.

Customers and end markets

End market: patients with inherited and age-related degenerative retinal diseases, specifically retinitis pigmentosa. No commercial customers as of the filing. Collaboration partners include TOI (Phase 2 partner for KIO-301). Revenue counterparties are collaboration partners and government grant bodies.

Value-chain role

Drug discovery and clinical-stage development. Licenses foundational photoswitch molecule IP from University of California under an exclusive agreement requiring annual fees, development milestone payments, and royalties of 2% on first $250 million of net sales, 1.25% on net sales between $250 million and $500 million, and 0.5% on net sales above $500 million (per the amended UC license). Relies on external partners for clinical trial execution and regulatory filings in certain jurisdictions.

Geographic exposure

Primary operations in the United States. Collaboration and grant revenue includes foreign government grants. Foreign currency translation adjustments appear on the balance sheet, indicating some non-U.S. operational exposure.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Enveric Biosciences Inc AmeriCann, Inc. /entities/nasc Evoke Pharma Inc Grapefruit USA, Inc GREEN HYGIENICS HOLDINGS INC. Johnson & Johnson One World Products Inc Sonoma Pharmaceuticals Inc